CSL wins US Government contract for influenza vaccines
The contract has a maximum potential value of $1,511,407,737.78 if all optional activities are exercised over the duration of the contract. Under the terms of the contract, the
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
Pursuant to the agreement, screening and hit-to-lead chemistry will take place in the Broad’s Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified,
The software allows biotech customers to leverage Bruker’s mass spectrometry for intact protein and post-translational modification analysis in a routine industrial biologics environment. The solution introduced techniques for